Opinion|Videos|October 9, 2023
Untapped Potentials - Exploring Overlooked Therapies for Type 2 Diabetes
In this episode of MEDcast, the expert panelists examine some underutilized therapies in type 2 diabetes (T2D) and explore their potential as effective treatment choices for many patients.
Advertisement
Episodes in this series
0:50 Need for using older diabetes medications
3:30 Quick-release bromocriptine: benefits in T2D and cardiovascular risk
6:15 Efficacy of quick-release bromocriptine
8:10 Quick-release bromocriptine as monotherapy and as an add-on
9:00 Mechanism of quick-release bromocriptine
11:41 Titrating quick-release bromocriptine
15:50 Benefits of pioglitazone
22:30 Positioning older T2D therapies in the current treatment regimen
Advertisement
Related to this article
EloraTZP cut body weight by up to 23.3% and A1C by up to 2.9% at 48 weeks vs 14.8% and 2.4% with tirzepatide 15 mg in a phase 2b trial.
Real-world COMPETE SWITCH CV data at EASD 2026 linked semaglutide 2 mg escalation to 6% lower MACE risk vs switching to tirzepatide in T2D.
Discover how newly cleared weekly basal insulin efsitora reshapes type 2 diabetes care—QWINT results, hypoglycemia edge, and dosing tips.
FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
Preview the biggest anticipated FDA decisions of Q4 2026, including bepirovirsen for CHB, obinutuzumab for pMN, bezuclastinib for systemic mastocytosis, and more.
Newly published results from the TRIUMPH-1 study have indicated the direct correlation between the triple agonist and several improvements to weight.
Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).
The FDA approved once-daily oral zilurgisertib for FOP in patients aged 12 years and older after the phase 2 PROGRESS trial showed reduced new heterotopic ossification vs placebo.
Advertisement
Advertisement
Trending on HCPLive
1
US Alcohol Use Falls, but Not for Adults Aged 50 to 64, With Brian Lee, MD
2
EASD 2026: EloraTZP Bests Tirzepatide on Weight Loss, A1C in Type 2 Diabetes
3
Nail Detachment 4 Times More Common With GLP-1 Use
4
FDA Approves Mavacamten for Pediatric Patients With Obstructive HCM
5